Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5601 in IgA Nephropathy
NCT06926985Phase 1Withdrawn
- Sponsor
- Jieyang People's Hospital
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5601 in IgA nephropathy (IgAN), sponsored by Jieyang People's Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 52 weeks and Incidence of Treatment Emergent Adverse Events at 52 weeks. Planned start Jul 2025; status: withdrawn.
02
Drugs
KN5601
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06926985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926985.